Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy
Clinical Journal of the American Society of Nephrology · 2025-11 · 20 (11) · 1564-1570
DOI: 10.2215/cjn.0000000816 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 09.09.2025. Verfasst von Jincan Zan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Kidney Division, Key Laboratory of Kidney Disease, Peking University Institute of Nephrology, Peking University First Hospital, Ministry of Health of…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Capital's Funds for Health Improvement and Research, the National High level hospital clinical research funding (high quality clinical research project of Peking University First Hospital, National Key Research and Development Program of China.
Abstract (Originalsprache)
Key Points Systemic glucocorticoids could reduce levels of total IgA and galactose-deficient IgA1 (Gd-IgA1) in IgA nephropathy patients, but the effect diminished after treatment discontinuation. The reduction in Gd-IgA1 levels correlates with a decrease in proteinuria in patients treated with glucocorticoids. However, the reduction in Gd-IgA1 levels at 6 months during the treatment is not associated with long-term kidney outcomes.
Background
The Therapeutic Effects of Steroids in IgA Nephropathy Global trial demonstrated that glucocorticoid therapy reduced proteinuria and improved kidney outcomes in patients with IgA nephropathy. Galactose-deficient IgA1 (Gd-IgA1) plays a central role in IgA nephropathy pathogenesis by promoting immune complex formation. However, the effects of glucocorticoid on pathogenic IgA levels remain unclear. This study aimed to evaluate the effect of systemic glucocorticoids on serum total IgA and Gd-IgA1 levels in patients with IgA nephropathy in the Therapeutic Effects of Steroids in IgA Nephropathy Global trial.
Methods
Serum samples from 137 participants in the China Cohort were collected at baseline, 6, and 12 months. We measured the levels of total IgA and Gd-IgA1. The association between the changes in these markers and proteinuria reduction was analyzed. A linear mixed model was used to compare the changes in total IgA and Gd-IgA1 across each arm from baseline at 6 and 12 months.
Results
At 6 months, the reduced dose group showed a 27.2% (95% confidence interval, 16.4% to 36.6%) reduction in IgA and a 21.2% (10.6% to 30.6%) reduction in Gd-IgA1 compared with the placebo group. The full dose group exhibited reductions of 34% (25.7% to 41.4%) and 42.7% (36.1% to 48.6%), respectively. At 12 months, Gd-IgA1 decrement in the reduced dose group were similar compared to placebo by 4.6% (−8.3% to 15.9%, P = 0.47), while the full dose group maintained a significant reduction of 25.4% (16.8% to 33.1%, P < 0.001). A positive correlation was found between changes in total IgA, Gd-IgA1, and proteinuria reduction in the methylprednisolone groups, whereas no significant correlation was observed in the placebo group. The reduction in Gd-IgA1 levels at 6 months was not associated with long-term kidney progression events ( P = 0.49).
Conclusions
Systemic glucocorticoids significantly reduce total IgA and Gd-IgA1 levels in IgA nephropathy compared with placebo; however, the treatment effects may diminish over time. Clinical Trial registry name and registration number: NCT01560052.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kidney Division, Key Laboratory of Kidney Disease, Peking University Institute of Nephrology, Peking University First Hospital, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatm…
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
- Department of Kidney Medicine, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
ORCID-Profile: Jingyi Li, Muh Geot Wong, Dana Kim, Sufang Shi
Förderung
- Capital's Funds for Health Improvement and Research
- the National High level hospital clinical research funding (high quality clinical research project of Peking University First Hospital
- National Key Research and Development Program of China
Zitieren
APA
Zan, J., Li, J., Wong, M. G., Kim, D., Shi, S., Monaghan, H., Perkovic, V., Lv, J., Zhang, H., & TESTING study biomarker group (2025). Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy. Clinical Journal of the American Society of Nephrology, 20(11), 1564-1570. https://doi.org/10.2215/cjn.0000000816
Vancouver
Zan J, Li J, Wong MG, Kim D, Shi S, Monaghan H, et al. Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy. Clinical Journal of the American Society of Nephrology. 2025;20(11):1564-1570. doi:10.2215/cjn.0000000816
BibTeX
@article{Zan2025,
author = {Zan, Jincan and Li, Jingyi and Wong, Muh Geot and Kim, Dana and Shi, Sufang and Monaghan, Helen and Perkovic, Vlado and Lv, Jicheng and Zhang, Hong and TESTING study biomarker group, TESTING study biomarker group},
title = {Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2025},
volume = {20},
number = {11},
pages = {1564--1570},
doi = {10.2215/cjn.0000000816}
}
EUVIMED